These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33758897)

  • 21. Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina.
    Longueira Y; Polo ML; ; ; Turk G; Laufer N
    Heliyon; 2021 Oct; 7(10):e08140. PubMed ID: 34642643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2
    Salazar E; Kuchipudi SV; Christensen PA; Eagar TN; Yi X; Zhao P; Jin Z; Long SW; Olsen RJ; Chen J; Castillo B; Leveque C; Towers DM; Lavinder J; Gollihar JD; Cardona J; Ippolito GC; Nissly RH; Bird IM; Greenawalt D; Rossi RM; Gontu A; Srinivasan S; Poojary IB; Cattadori IM; Hudson PJ; Joselyn N; Prugar L; Huie K; Herbert A; Bernard DW; Dye J; Kapur V; Musser JM
    bioRxiv; 2020 Jun; ():. PubMed ID: 32577662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.
    Racine-Brzostek SE; Yang HS; Jack GA; Chen Z; Chadburn A; Ketas TJ; Francomano E; Klasse PJ; Moore JP; McDonough KA; Girardin RC; Dupuis AP; Payne AF; Ma LX; Sweeney J; Zhong E; Yee J; Cushing MM; Zhao Z
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2025-e2034. PubMed ID: 33524125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
    Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
    Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.
    Bonny TS; Patel EU; Zhu X; Bloch EM; Grabowski MK; Abraham AG; Littlefield K; Shrestha R; Benner SE; Laeyendecker O; Shoham S; Sullivan D; Quinn TC; Casadevall A; Pekosz A; Redd AD; Tobian AAR
    Open Forum Infect Dis; 2021 Feb; 8(2):ofaa574. PubMed ID: 33553467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience.
    Kumar PK; Banerjee M; Bajpayee A; Mandal S; Mitra P; Sharma P; Misra S; Bhardwaj P
    Indian J Clin Biochem; 2022 Oct; 37(4):423-431. PubMed ID: 34812224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
    Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
    Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictors of high titer of
    Wardhani SO; Fajar JK; Nurarifah N; Hermanto DH; Fatonah S; Djajalaksana S; Fatoni AZ; Arsana PM; Wulandari L; Soegiarto G; Dhama K; Harapan H
    Clin Epidemiol Glob Health; 2021; 11():100763. PubMed ID: 33997476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.
    Schiffner J; Backhaus I; Rimmele J; Schulz S; Möhlenkamp T; Klemens JM; Zapf D; Solbach W; Mischnik A
    Front Public Health; 2021; 9():732787. PubMed ID: 34646805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
    Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
    Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers.
    Padoan A; Bonfante F; Cosma C; Di Chiara C; Sciacovelli L; Pagliari M; Bortolami A; Costenaro P; Musso G; Basso D; Giaquinto C; Plebani M
    Clin Chem Lab Med; 2021 Jul; 59(8):1444-1452. PubMed ID: 33855843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
    Anand SP; Prévost J; Nayrac M; Beaudoin-Bussières G; Benlarbi M; Gasser R; Brassard N; Laumaea A; Gong SY; Bourassa C; Brunet-Ratnasingham E; Medjahed H; Gendron-Lepage G; Goyette G; Gokool L; Morrisseau C; Bégin P; Martel-Laferrière V; Tremblay C; Richard J; Bazin R; Duerr R; Kaufmann DE; Finzi A
    bioRxiv; 2021 Jan; ():. PubMed ID: 33532774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.
    Wouters E; Verbrugghe C; Devloo R; Debruyne I; De Clippel D; Van Heddegem L; Van Asch K; Van Gaver V; Vanbrabant M; Muylaert A; Compernolle V; Feys HB
    Transfusion; 2021 Oct; 61(10):2981-2990. PubMed ID: 34498761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.
    Steenhuis M; van Mierlo G; Derksen NI; Ooijevaar-de Heer P; Kruithof S; Loeff FL; Berkhout LC; Linty F; Reusken C; Reimerink J; Hogema B; Zaaijer H; van de Watering L; Swaneveld F; van Gils MJ; Bosch BJ; van Ham SM; Ten Brinke A; Vidarsson G; van der Schoot EC; Rispens T
    Clin Transl Immunology; 2021; 10(5):e1285. PubMed ID: 34026115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal SARS-CoV-2 Seroconversion Course and Antibody Levels by Blood Groups in Convalescent Plasma Donors in Turkey.
    Karaca A; Guncikan MN; Sozmen NN; Karadag GG; Yilmaz M; Kinik K; Yilmaz FM
    Medeni Med J; 2021; 36(3):185-192. PubMed ID: 34915675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability.
    Laner-Plamberger S; Lindlbauer N; Weidner L; Gänsdorfer S; Weseslindtner L; Held N; Lauth W; Zimmermann G; Kern JM; Föttinger F; Ombres L; Jungbauer C; Rohde E; Grabmer C
    Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.